Cardiorenal Benefits of Aortix™ Device to be Presented at ACC.15 in San Diego, CA
Research shows reduced workload of the heart, decreased oxygen demand.
Houston, TX, March 14, 2015 --(PR.com)-- Carlos del Rio, Ph.D. of QTest Laboratories will present his findings using Aortix,™ a catheter-deployed circulatory assist pump for the treatment of chronic heart failure being developed by Procyrion, Inc., at the American College of Cardiology’s 64th Annual Scientific Session and Expo (ACC.15) to be held March 14 – 16, 2015 in San Diego, California. Based in Columbus, Ohio, Qtest Labs provides comprehensive cardiovascular research and development solutions to pharmaceutical and biotechnology companies.
In a poster presentation, del Rio will highlight his research on the acute cardiorenal benefits and improved ventriculo-arterial coupling of Aortix™ during a session entitled: “Stage D and Beyond: Advanced Heart Failure, Mechanical Circulatory Support and Transplantation” on Saturday, March 14 from 9:30 a.m. – 12:30 p.m.
“This research, performed by QTest labs in sheep with ischemic chronic heart failure, demonstrates that Aortix™ reduces the workload of the heart, decreasing oxygen demand, which may help the heart rest and heal while dramatically improving kidney function. These results exceeded our expectations and is further evidence that Aortix could be used to support the failing heart before years of progressive damage occur,” says Procyrion Director of Research and Development, Will Clifton, MD.
Thinner than a #2 pencil, Aortix™ is delivered by a catheter inserted through the femoral artery and held in place using novel self-expanding anchors. The small size and unique design enable the pump to be placed in a ten-minute outpatient procedure. Conceived by Dr. Reynolds M. Delgado III, Medical Director of Mechanical Support at the Texas Heart Institute, Aortix™ is expected to be a treatment option for millions of chronic heart failure patients who are too sick for medication alone.
Abstracts at ACC.15 will be presented in 46 topic areas focusing on the prevention, diagnosis and treatment of cardiovascular disease.
Recently, Procyrion was named a HATCH pitch finalist and will compete for top prize at SXSW in Austin, Texas on March 16. The company has also been accepted to present at the International Society for Heart and Lung Transplantation’s 35th Annual Meeting & Scientific Session in Nice, France April 15 – 18, 2015.
For more information about Qtest Laboratories, visit www.qtestlabs.com or call 614.760.0800.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
About QTest Las
QTest Labs is a pre-clinical contract research organization that specializes in cardiovascular safety, complete risk assessment, and the ex/in vivo evaluation of physiology, electrophysiology, toxicology, and pharmacology in both normal and diseased models. Via a patent-pending paradigm and the extensive scientific expertise, QTest Labs aims to provide a comprehensive and clear mechanistic understanding of novel drugs and/or devices.
About The American College of Cardiology
The American College of Cardiology is a 47,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.
In a poster presentation, del Rio will highlight his research on the acute cardiorenal benefits and improved ventriculo-arterial coupling of Aortix™ during a session entitled: “Stage D and Beyond: Advanced Heart Failure, Mechanical Circulatory Support and Transplantation” on Saturday, March 14 from 9:30 a.m. – 12:30 p.m.
“This research, performed by QTest labs in sheep with ischemic chronic heart failure, demonstrates that Aortix™ reduces the workload of the heart, decreasing oxygen demand, which may help the heart rest and heal while dramatically improving kidney function. These results exceeded our expectations and is further evidence that Aortix could be used to support the failing heart before years of progressive damage occur,” says Procyrion Director of Research and Development, Will Clifton, MD.
Thinner than a #2 pencil, Aortix™ is delivered by a catheter inserted through the femoral artery and held in place using novel self-expanding anchors. The small size and unique design enable the pump to be placed in a ten-minute outpatient procedure. Conceived by Dr. Reynolds M. Delgado III, Medical Director of Mechanical Support at the Texas Heart Institute, Aortix™ is expected to be a treatment option for millions of chronic heart failure patients who are too sick for medication alone.
Abstracts at ACC.15 will be presented in 46 topic areas focusing on the prevention, diagnosis and treatment of cardiovascular disease.
Recently, Procyrion was named a HATCH pitch finalist and will compete for top prize at SXSW in Austin, Texas on March 16. The company has also been accepted to present at the International Society for Heart and Lung Transplantation’s 35th Annual Meeting & Scientific Session in Nice, France April 15 – 18, 2015.
For more information about Qtest Laboratories, visit www.qtestlabs.com or call 614.760.0800.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
About QTest Las
QTest Labs is a pre-clinical contract research organization that specializes in cardiovascular safety, complete risk assessment, and the ex/in vivo evaluation of physiology, electrophysiology, toxicology, and pharmacology in both normal and diseased models. Via a patent-pending paradigm and the extensive scientific expertise, QTest Labs aims to provide a comprehensive and clear mechanistic understanding of novel drugs and/or devices.
About The American College of Cardiology
The American College of Cardiology is a 47,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.
Contact
Procyrion Inc
Anna Drake
713.510.0500
www.procyrion.com
Anna Drake
713.510.0500
www.procyrion.com
Contact
Categories